Table 2:
Risk of neurocognitive impairment associated with treatment exposures
| Domaina | ||||
|---|---|---|---|---|
| Exposure | Task efficiency | Emotional regulation | Organization | Memory |
| RR (95% CI) | ||||
| Age ≤ 1 at diagnosis | ||||
| Model 1: Demographics and treatmentb | ||||
| Male | 1.14 (0.77–1.71) | 0.65 (0.43–0.98) | 0.98 (0.69–1.38) | 1.05 (0.70– 1.58) |
| Non-Hispanic white | 1.35 (0.69–2.66) | 0.99 (0.54–1.81) | 1.28 (0.71–2.31) | 0.89 (0.50–1.58) |
| Abdominal/pelvic/TBI radiation | 1.11 (0.62–2.01) | 0.88 (0.45–1.70) | 1.24 (0.78–1.97) | 1.36 (0.78–2.38) |
| Thoracic/TBI radiationc | 0.49 (0.18–1.32) | 0.24 (0.06–1.06) | 0.84 (0.44–1.59) | 0.61 (0.24–1.56) |
| Brain radiationd | 0.80 (0.25–2.56) | 0.92 (0.26–3.26) | 0.67 (0.19–2.42) | 0.79 (0.22–2.85) |
| Platinum | 1.74 (1.01–2.97) | 1.36 (0.83–2.24) | 1.06 (0.67–1.68) | 1.27 (0.76–2.13) |
| Cyclophosphamide | 0.99 (0.97–1.02) | 1.01 (0.98–1.03) | 0.99 (0.97–1.01) | 0.99 (0.96–1.01) |
| Anthracycline | 0.99 (0.59–1.68) | 1.07 (0.66–1.72) | 1.18 (0.78–1.79) | 1.36 (0.82–2.26) |
| Model 2: Treatment Erae | ||||
| 1970–1979 | 1.31 (0.67–2.55) | 1.48 (0.74–2.95) | 1.89 (1.09–3.29) | 1.21 (0.61–2.40) |
| 1980–1989 | 0.92 (0.57–1.47) | 1.38 (0.82–2.33) | 1.48 (0.95–2.31) | 1.28 (0.76–2.16) |
| 1990–1999 | Reference | Reference | Reference | Reference |
| Age > 1 at diagnosis | ||||
| Model 1: Demographics and treatmentb | ||||
| Male | 0.66 (0.42–1.02) | 0.66 (0.43–1.03) | 0.98 (0.67–1.44) | 0.73 (0.47–1.15) |
| Non-Hispanic white | 0.86 (0.52–1.43) | 0.39 (0.26–0.58) | 1.13 (0.66–1.94) | 1.01 (0.57–1.80) |
| Abdominal/pelvic/TBI radiation | 1.27 (0.84–1.92) | 1.30 (0.82–2.05) | 1.10 (0.70–1.72) | 1.07 (0.65–1.76) |
| Thoracic/TBI radiationc | 0.95 (0.57–1.57) | 0.41 (0.23–0.76) | 0.88 (0.53–1.45) | 0.59 (0.33–1.05) |
| Brain radiationd | 1.22 (0.68–2.18) | 1.96 (1.05–3.65) | 0.67 (0.32–1.38) | 2.02 (1.14–3.58) |
| Platinum | 1.07 (0.60–1.92) | 0.79 (0.43–1.45) | 0.93 (0.49–1.74) | 1.25 (0.63–2.46) |
| Cyclophosphamide | 0.98 (0.95–1.01) | 1.00 (0.99–1.02) | 0.99 (0.96–1.02) | 0.99 (0.97–1.02) |
| Anthracycline | 1.06 (0.59–1.91) | 1.25 (0.69–2.26) | 1.22 (0.65–2.30) | 0.98 (0.48–1.98) |
| Model 2: Treatment Erae | ||||
| 1970–1979 | 1.16 (0.65–2.07) | 1.77 (1.02–3.06) | 1.2 (0.71–2.03) | 0.73 (0.39–1.39) |
| 1980–1989 | 1.12 (0.76–1.65) | 1.25 (0.79–1.98) | 1.1 (0.74–1.64) | 0.94 (0.61 −1.45) |
| 1990–1999 | Reference | Reference | Reference | Reference |
Abbreviations: RR= Relative Risk; 95% CI= confidence interval; TBI= Total body irritation
a
Impairment is defined as a score ≥90th percentile of the siblings’ distribution
b
Treatment is categorized as yes/no;
c
Thoracic/TBI includes patients who got chest radiation
d
Brain radiation includes exposure to cranial, cranial spinal and or TBI
e
Model adjusted for age at follow-up, sex, and race/ethnicity